key: cord-0895199-6h26dg67
authors: Marcelino, João; Farinha, Sofia; Silva, Rita; Didenko, Irina; Proença, Miguel; Tomás, Elza
title: Non-irritant concentrations for skin testing with SARS-CoV-2 mRNA Vaccine
date: 2021-03-23
journal: J Allergy Clin Immunol Pract
DOI: 10.1016/j.jaip.2021.03.022
sha: 17432b73cad8f44605f8318d6529578abd56dc94
doc_id: 895199
cord_uid: 6h26dg67

nan

Pfizer's specifications regarding the vaccine use states that each vial contains enough for 5 doses 54 with a six-hour viability before inoculation. In some settings, healthcare professionals have used the surplus 55 in each vial for an additional 6th dose. Even in these cases, each vial still contains a small quantity of 56 vaccine, which can be used to perform skin tests. 57

Taking advantage of this fact, we evaluated 55 healthcare professionals to determine non-irritant 58 concentrations for skin testing with SARS-CoV-2 mRNA Vaccine. 59 mediated allergy to penicillin and NSAID-induced asthma and urticaria (previously confirmed by an 76 allergologist). 77

All the skin prick tests with histamine were positive (wheals between 4x4 mm and 9x8 mm). All 78 negative control prick tests were negative with the exception of a patient with symptomatic 79 dermographism (wheal of 5x5 mm). 

Allergic rhinitis confirmed by allergic testing 11

Non-allergic rhinitis confirmed by allergic testing 1

Rhinitis-like symptoms with no previous evaluation by allergology 6

Allergic asthma confirmed by allergic testing 10

Non-allergic asthma confirmed by allergic testing 1

Asthma-like symptoms with no previous evaluation by allergology 

Maintaining Safety with SARS-CoV-2 Vaccines

Immediate-type hypersensitivity to polyethylene glycols: a review

Skin test 105 concentrations for systemically administered drugs --an ENDA/EAACI Drug Allergy Interest Group position 106 paper

General considerations for skin 108 test procedures in the diagnosis of drug hypersensitivity